T cell vaccination ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01448252 (ClinicalTrials.gov)	May 2002	5/10/2011	T Cell Vaccination in Patients With Progressive Multiple Sclerosis	Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis	Multiple Sclerosis	Biological: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides);Biological: T cell vaccination	Hadassah Medical Organization	NULL	Completed	18 Years	60 Years	Both	30	Phase 1/Phase 2	Israel
2	NCT00228228 (ClinicalTrials.gov)	May 2002	26/9/2005	TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis	T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis	Multiple Sclerosis	Biological: T cell vaccination	Sheba Medical Center	NULL	Recruiting	15 Years	50 Years	Both	80	Phase 3	Israel